…
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Denali Therapeutics is a clinical-stage biotech developing targeted therapies for neurodegenerative diseases using a proprietary blood–brain barrier transport platform to improve CNS delivery. Long-term growth drivers include clinical readouts, validation of the delivery platform and potential collaborations to support development. Investors may find it attractive because it appears positioned to address unmet needs in CNS disorders where brain delivery limits current treatments.
Principal risks are material clinical and regulatory uncertainty, development-stage financing needs and competition from larger companies pursuing alternative CNS approaches.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -512.44M | -422.70M | -145.19M | -325.97M | -291.16M |
| Net income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M |
| Selling general administrative | 97.10M | 105.44M | 103.35M | 90.47M | 79.06M |
| Selling and marketing expenses | - | - | 16.73M | - | - |
| Gross profit | -11.18M | -7.79M | 330.53M | 108.46M | 48.66M |
| Reconciled depreciation | 14.81M | 8.99M | 18.64M | 10.38M | 8.59M |
| Ebit | -512.44M | -501.88M | -196.70M | -340.74M | -304.34M |
| Ebitda | -497.63M | -492.89M | -179.97M | -330.36M | -295.75M |
| Depreciation and amortization | 14.81M | 8.99M | 16.73M | 10.38M | 8.59M |
| Non operating income net other | - | - | - | - | 4.59M |
| Operating income | -555.34M | -487.34M | -196.70M | -340.74M | -295.75M |
| Other operating expenses | 555.34M | 487.34M | 527.23M | 449.21M | 344.41M |
| Interest expense | - | - | - | 14.77M | 13.19M |
| Tax provision | 0.10M | 0.07M | -0.01M | 0.02M | -0.57M |
| Interest income | 42.90M | 64.64M | 51.51M | 14.77M | 4.59M |
| Net interest income | 42.90M | 64.64M | 45.04M | 14.77M | 4.59M |
| Income tax expense | 0.10M | 0.07M | 0.03M | 0.02M | -0.57M |
| Total revenue | 0.00M | 0.00M | 330.53M | 108.46M | 48.66M |
| Total operating expenses | 544.16M | 487.34M | 527.23M | 449.21M | 344.41M |
| Cost of revenue | 11.18M | 7.79M | 16.73M | - | - |
| Total other income expense net | 42.90M | 64.64M | 51.51M | 14.77M | 4.59M |
| Net income from continuing ops | -512.54M | -422.77M | -124.43M | -325.99M | -290.58M |
| Net income applicable to common shares | - | - | - | -325.99M | -290.58M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1144.85M | 1374.18M | 1153.92M | 1460.24M | 1404.16M |
| Other current assets | 30.60M | 29.93M | 26.93M | 36.10M | 30.60M |
| Total liab | 131.09M | 144.50M | 122.96M | 417.81M | 441.87M |
| Total stockholder equity | 1013.76M | 1229.68M | 1030.95M | 1042.43M | 962.29M |
| Other current liab | 85.47M | 79.04M | 61.24M | 63.76M | 47.71M |
| Common stock | 1.89M | 1.77M | 1.71M | 1.69M | 1.55M |
| Capital stock | 1.89M | 1.77M | 1.71M | 1.69M | 1.55M |
| Retained earnings | -2051.52M | -1538.98M | -1116.21M | -970.99M | -645.00M |
| Other liab | - | - | - | 0.86M | 5.07M |
| Other assets | - | - | 0.00M | 13.40M | 11.87M |
| Cash | 205.33M | 174.96M | 127.11M | 218.04M | 293.48M |
| Total current liabilities | 98.35M | 102.21M | 77.98M | 363.92M | 378.25M |
| Current deferred revenue | - | - | - | 290.05M | 320.30M |
| Net debt | -163.04M | -126.25M | -74.86M | -157.69M | -234.92M |
| Short term debt | 9.55M | 12.03M | 7.26M | 7.32M | 5.45M |
| Short long term debt total | 42.29M | 48.71M | 52.24M | 60.35M | 58.55M |
| Other stockholder equity | 3062.72M | 2764.88M | 2144.81M | 2018.62M | 1608.24M |
| Property plant equipment | - | - | - | 74.52M | 69.61M |
| Total current assets | 900.66M | 864.44M | 1064.14M | 1372.32M | 897.23M |
| Long term investments | 98.32M | 359.37M | - | 0.00M | 425.45M |
| Net tangible assets | - | - | - | 1042.43M | 962.29M |
| Short term investments | 662.55M | 657.37M | 907.40M | 1118.17M | 571.93M |
| Net receivables | 2.18M | 2.17M | 2.70M | - | 1.23M |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 3.33M | 11.14M | 9.48M | 2.79M | 4.78M |
| Accumulated other comprehensive income | 0.68M | 2.02M | 0.64M | -6.89M | -2.50M |
| Common stock total equity | - | - | - | - | 1.55M |
| Retained earnings total equity | - | - | - | - | -645.00M |
| Non currrent assets other | 124.26M | 24.74M | 16.54M | 13.40M | 11.87M |
| Non current assets total | 244.20M | 509.74M | 89.78M | 87.92M | 506.93M |
| Capital lease obligations | 36.76M | 48.71M | 52.24M | 60.35M | 58.55M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 264.78M | -88.76M | 48.70M | -141.39M | -13.13M |
| Change to liabilities | - | - | - | -32.19M | -11.96M |
| Total cashflows from investing activities | 255.28M | -88.76M | 249.31M | -141.39M | -21.63M |
| Net borrowings | -8.17M | -32.34M | 0.00M | - | - |
| Total cash from financing activities | 189.22M | 484.30M | 17.82M | 310.67M | 19.35M |
| Change to operating activities | - | - | - | 8.16M | -8.46M |
| Net income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M |
| Change in cash | 31.90M | 47.85M | -90.94M | -75.43M | -213.67M |
| Begin period cash flow | 176.53M | 128.68M | 218.04M | 294.98M | 508.64M |
| End period cash flow | 208.43M | 176.53M | 127.11M | 219.54M | 294.98M |
| Total cash from operating activities | -412.60M | -347.69M | -357.99M | -244.72M | -211.39M |
| Issuance of capital stock | 189.25M | 499.25M | 0.00M | 296.21M | 0.00M |
| Depreciation | 14.81M | 8.99M | 16.73M | 10.38M | 8.59M |
| Sale purchase of stock | - | - | - | - | 19.35M |
| Other cashflows from financing activities | 189.22M | 17.39M | 17.82M | 14.46M | 19.35M |
| Change to netincome | - | - | - | 94.92M | 91.01M |
| Capital expenditures | 9.50M | 15.91M | 12.94M | 17.83M | 8.50M |
| Cash flows other operating | - | - | - | - | -31.51M |
| Cash and cash equivalents changes | - | - | - | - | -213.67M |
| Change in working capital | 0.15M | 16.94M | -289.93M | -24.03M | -20.41M |
| Stock based compensation | 99.63M | 102.88M | 108.10M | 99.85M | 85.25M |
| Other non cash items | -14.65M | -53.73M | -47.67M | -4.92M | -2.98M |
| Free cash flow | -422.10M | -363.61M | -370.93M | -262.55M | -219.89M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics Inc |
0.42 2.33% |
18.42 | - | - | 3643.65 | 3.21 | 2843.16 | 86.48 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
650 866 8547
503
| Name | Title | Year Born |
|---|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, Pres, CEO & Director | 1976 |
| Dr. Alexander O. Schuth M.D. | Co-Founder, CFO, COO & Sec. | 1973 |
| Dr. Marc Tessier-Lavigne Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 1960 |
| Dr. Carole Ho M.D. | Chief Medical Officer & Head of Devel. | 1973 |
| Mr. Steve Edward Krognes | Treasurer & Director | 1968 |
| Mr. Tyler M. Nielsen | Sr. VP of Corp. Fin. | 1978 |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer | NA |
| Mr. Joe Lewcock | Chief Scientific Officer | NA |
| Dr. Laura Hansen | VP of Investor Relations | NA |
| Mr. Chris Walsh | Gen. Counsel | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.